Open Access<p>Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells</p>
Author(s) -
Bingren Hu,
Huajie Cai,
Shouzhang Yang,
Jinfu Tu,
Xu Huang,
Gang Chen
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s223242
Subject(s) - stat3 , signal transduction , cell cycle , chemistry , apoptosis , cancer research , gefitinib , egfr inhibitors , cell growth , microbiology and biotechnology , epidermal growth factor receptor , receptor , biology , biochemistry
Small molecular inhibitors such as gefitinib (Gefi), which target EGF receptor (EGFR), are considered to be a viable pathway for the selective inhibition of pancreatic cancer (PC) development. However, the large difference in Gefi response between PC patient individuals and PC cell lines severely limits the clinical efficacy of Gefi. Berbamine (BBM) is a well-known natural-derived antitumor agent. However, no study yet exists on whether BBM can enhance the sensitivity of PC cells to Gefi or its underlying mechanisms.